化合物 T28775
|
|
|
- CAS号:
- 172927-65-0
- 英文名:
- Sibrafiban
- 英文别名:
- Sibrafiban;WBNUCLPUOSXSNJ-UHFFFAOYSA-N;Acetic acid, 2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester
- 中文名:
- 化合物 T28775
- 中文别名:
- 化合物 T28775
- CBNumber:
- CB41179738
- 分子式:
- C20H28N4O6
- 分子量:
- 420.46
- MOL File:
- 172927-65-0.mol
|
|
|
化合物 T28775化学性质
-
密度:
-
1.33±0.1 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO : 33.33 mg/mL (79.27 mM; Need ultrasonic)
-
|
-
形态:
-
Solid
-
|
-
酸度系数(pKa):
-
13.16±0.10(Predicted)
-
|
-
颜色:
-
White to off-white
-
|
化合物 T28775性质、用途与生产工艺
Sibrafiban (RO 48-3657) 是一种 Ro 44-3888 的具有口服活性的，非肽，双重前药，是一种选择性的糖蛋白 IIb/IIIa 受体 (glycoprotein IIb/IIIa receptor) 拮抗剂。Sibrafiban 可抑制血小板聚集。
Glycoprotein IIb/IIIa receptor
The effects of site occupancy by Sibrafiban on platelet activation are assessed using P-selectin expression, fibrinogen binding and microaggregate formation. Sibrafiban inhibits ADP and TRAP-stimulated fibrinogen binding and microaggregate formation in a concentration-dependent manner, whereas P-selectin expression is relatively unaltered. A decrease in site occupancy from peak to trough of Sibrafiban does not result in increased activation of platelets.
The effects of Ro 44-3888 on the platelet aggregation response to ADP (17 μmol) and on cutaneous bleeding times is determined in 8 rhesus monkeys given Sibrafiban 0.25 mg/kg/day or 0.5 mg/kg/day orally for 8 days. The maximum inhibition of ex vivo platelet aggregation and prolongation of bleeding time by Ro 44-3888 are dose dependent.
化合物 T28775
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-10309 | Sibrafiban | 172927-65-0 | 5 mg | 3000元 |
| 2024/04/30 | HY-10309 | Sibrafiban | | 10 mg | 4800元 |
172927-65-0, 化合物 T28775 相关搜索:
- 化合物 T28775
- 172927-65-0
- WBNUCLPUOSXSNJ-UHFFFAOYSA-N
- Acetic acid, 2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-, ethyl ester
- Sibrafiban